Evidence map›Paper›PMID 41258720›Full record

ReviewImmunological reviews2025

Ontogenetic Diversification of Type 2 Conventional Dendritic Cells in the Bone Marrow: A Central Logic for Peripheral Immunity.

Robert W Baber, Miguel  Magalhães-Patrício, Maria V Pires, Vasco Correia, Juan M Lozano-Gil, João C Guimarães, Chrysothemis C Brown, Marc Dalod, Carlos M Minutti

Abstract readReview
In one paragraph

Review in Immunological reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Robert W BaberChampalimaud Foundation, Champalimaud Centre for the Unknown, Immunoregulation Group, Lisbon, Portugal.
Miguel  Magalhães-PatrícioChampalimaud Foundation, Champalimaud Centre for the Unknown, Immunoregulation Group, Lisbon, Portugal.ORCID https://orcid.org/0009-0001-5747-5547
Maria V PiresChampalimaud Foundation, Champalimaud Centre for the Unknown, Immunoregulation Group, Lisbon, Portugal.ORCID https://orcid.org/0009-0000-6835-310X
Vasco CorreiaChampalimaud Foundation, Champalimaud Centre for the Unknown, Immunoregulation Group, Lisbon, Portugal.
Juan M Lozano-GilChampalimaud Foundation, Champalimaud Centre for the Unknown, Immunoregulation Group, Lisbon, Portugal.ORCID https://orcid.org/0000-0002-0422-9887
João C GuimarãesFaculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.
Chrysothemis C BrownImmune Oncology Program, Howard Hughes Medical Institute, and Department of Pediatrics, Memorial Sloan Kettering Cancer Center and Immunology and Microbial Pathogenesis Program, Weill Cornell Medicine Graduate School of Medical Sciences, New York, New York, USA.ORCID https://orcid.org/0000-0002-5834-926X
Marc DalodAix-Marseille University, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Centre D'immunologie de Marseille-Luminy, Turing Center for Living Systems, Marseille, France.ORCID https://orcid.org/0000-0002-6436-7966
Carlos M MinuttiChampalimaud Foundation, Champalimaud Centre for the Unknown, Immunoregulation Group, Lisbon, Portugal.ORCID https://orcid.org/0000-0002-9663-1928

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
European Hematology Association KOG-202409-06691European Research Council 101116335HORIZON EUROPE European Innovation Council 952377NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Type 2 conventional dendritic cells (cDC2s) are central orchestrators of adaptive immunity. While historically considered a single population shaped by local microenvironments, recent evidence indicates that cDC2s comprise developmentally distinct subsets-cDC2As and cDC2Bs-with divergent ontogeny, tissue distribution, and immune functions. This review synthesizes current advances in the identification, differentiation, and functional characterization of these cDC2 subsets, with a focus on data supporting an early bifurcation at the level of bone marrow progenitors. We highlight how transcription factors such as TCF4 (and RBPJ) and KLF4 delineate cDC2A and cDC2B fates, respectively, and how subset-specific localization within tissues may amplify their distinct roles in immunity. We propose that early cDC2 diversification reflects a broader principle of central immune preconfiguration, in which the bone marrow senses peripheral immunological states and anticipates tissue-specific demands through progenitor programming. This hypothetical model redefines cDC2s not merely as adaptable responders to local cues, but as a paradigm for how immune output can be systemically preconfigured. As such, they offer a powerful lens through which to study how development and function intersect across immunity. Recent findings suggest that the ontogenetic logic in mouse cDC2 development may extend to humans, offering meaningful avenues for translational exploration.

Indexed as

Bone MarrowBone Marrow CellsDendritic CellsAdaptive ImmunityAnimalsCell DifferentiationCell LineageHumansKruppel-Like Factor 4KLF4 protein, humanKruppel-Like Factor 4bone marrow programmingcDC2 heterogeneitydendritic cell functiondendritic cell ontogenyimmune nichesimmune priminginfectioninflammationT helper cells

Identifiers

PMID41258720
PMCPMC12628738

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.